Kewalramani becme the first female CEO of a large, public U.S. biotechnology company after immigrating from India at age 11 ...

Learn more about whether SoundHound AI, Inc. or Vertex, Inc. is a better investment based on AAII's A+ Investor grades, which ...

According to Benzinga Pro, Vertex Pharmaceuticals's peer group average for short interest as a percentage of float is 6.62%, ...

Now in preview, the latest Flash lets you adjust reasoning capabilities to balance cost and complexity. Here's how to try it ...

Vertex, Inc. (NASDAQ: VERX) has announced plans to release its first quarter 2025 financial results on Wednesday, May 7, 2025 ...

Indian American physician-scientist and business executive Reshma Kewalramani, the CEO of Vertex Pharmaceuticals, has been ...

A recent selloff of Neurocrine Biosciences stock feels unwarranted and may have created a contrarian buy opportunity. Learn ...

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 2.92% to $485.89 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 2.24% to ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $51.3, a high estimate of $61.00, and a low estimate of $31.00. A 14.64% drop is evident in the current ...

Vertex Solutions, a small business known for the manufacturing of systems integration and advanced training technologies, has ...

Fox News senior national correspondent Aishah Hasnie reports on former President Joe Biden's first public remarks since ...

Morgan Stanley lowered the firm’s price target on Vertex (VERX) to $55 from $60 and keeps an Overweight rating on the shares. The firm is ...